JP2006273718A - Method for producing levofloxacin-1/2 hydrate - Google Patents
Method for producing levofloxacin-1/2 hydrate Download PDFInfo
- Publication number
- JP2006273718A JP2006273718A JP2005090485A JP2005090485A JP2006273718A JP 2006273718 A JP2006273718 A JP 2006273718A JP 2005090485 A JP2005090485 A JP 2005090485A JP 2005090485 A JP2005090485 A JP 2005090485A JP 2006273718 A JP2006273718 A JP 2006273718A
- Authority
- JP
- Japan
- Prior art keywords
- levofloxacin
- water
- hydrate
- producing
- containing lower
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
本発明は抗菌性化合物である、レボフロキサシン・1/2水和物の製法に関し、更に詳細には、レボフロキサシンを再結晶させ、その1/2水和物を高収率で得るレボフロキサシン・1/2水和物の製法に関する。 The present invention relates to a method for producing levofloxacin 1/2 hydrate, an antibacterial compound, and more specifically, levofloxacin 1/2 which obtains the 1/2 hydrate in high yield by recrystallizing levofloxacin. It relates to a method for producing hydrates.
レボフロキサシン((S)−9−フルオロ−3−メチル−10−(4−メチル−1−ピペラジニル)−7−オキソ−2,3−ジヒドロ−7H−ピリド[1,2,3−de][1,4]ベンソオキサジン−6−カルボン酸)は高い抗菌力と高い安全性を有する化合物であり(特許文献1参照)、その1/2水和物は、優れた合成抗菌薬として知られている。 Levofloxacin ((S) -9-fluoro-3-methyl-10- (4-methyl-1-piperazinyl) -7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de] [1 , 4] benzoxazine-6-carboxylic acid) is a compound having high antibacterial activity and high safety (see Patent Document 1), and its 1/2 hydrate is known as an excellent synthetic antibacterial agent. Yes.
このレボフロキサシンには、上記した1/2水和物の他、結晶水の数の異なる1水和物や、水和物から脱水して生成する無水物の結晶の存在が知られているが、抗菌剤として使用するためには、これらを1/2水和物とすることが必要である。 In this levofloxacin, in addition to the above-mentioned 1/2 hydrate, there are known monohydrates having different numbers of water of crystallization, and the presence of anhydrous crystals produced by dehydration from hydrates. In order to use as an antibacterial agent, it is necessary to make these into 1/2 hydrate.
従来、レボフロキサシンの1/2水和物は、前記レボフロキサシンの1水和物や無水物(以下、「レボフロキサシン粗原料」という)の結晶をエタノールとジエチルエーテル若しくは濃アンモニア水とエタノールの混合溶媒(特許文献1参照)、もしくは4−11%の含水エタノール、含水アセトンで再結晶し、晶析させることにより得ていた。 Conventionally, levofloxacin hemihydrate is obtained by mixing a crystal of levofloxacin monohydrate or anhydride (hereinafter referred to as “levofloxacin crude material”) with a mixed solvent of ethanol and diethyl ether or concentrated aqueous ammonia and ethanol (patented) It was obtained by recrystallization from 4-11% hydrous ethanol or hydrous acetone and crystallization.
しかし、前者の混合溶媒を使用する方法では、晶析時に1/2水和物であるレボフロキサシンの他にレボフロキサシン粗原料の1水和物(以下、単に「1水和物」と略す)が析出し、これが混入する場合があった。また、後者の場合においても、1水和物が析出し、混入する場合もあり、高純度のレボフロキサシンを得る方法としては不十分であった。 However, in the former method using the mixed solvent, levofloxacin crude raw material monohydrate (hereinafter simply referred to as “monohydrate”) is precipitated in addition to levofloxacin, which is a half hydrate, at the time of crystallization. However, this may be mixed. In the latter case, monohydrate may be precipitated and mixed, which is insufficient as a method for obtaining high-purity levofloxacin.
従って、レボフロキサシン粗原料を、高収率でレボフロキサシン・1/2水和物に変えることのできる方法の開発が求められており、このような方法を提供することが本発明の課題である。 Accordingly, there is a demand for the development of a method capable of changing the raw levofloxacin raw material to levofloxacin 1/2 hydrate with a high yield, and it is an object of the present invention to provide such a method.
本発明者は、上記課題を解決すべく、レボフロキサシン・1/2水和物を得るための再結晶方法に関し、鋭意検討を行っていたところ、ごく低い含水率の溶媒中でレボフロキサシンを再結晶することで、レボフロキサシンの1/2水和物を安定的かつ高収率で取得可能であることを見いだし、本発明を完成した。 In order to solve the above problems, the present inventor has intensively studied a recrystallization method for obtaining levofloxacin 1/2 hydrate, and recrystallizes levofloxacin in a solvent having a very low water content. Thus, it was found that levofloxacin hemihydrate can be obtained stably and in high yield, and the present invention was completed.
すなわち本発明は、レボフロキサシンを、含水率が0.14容量%以上4容量%未満である含水低級アルコール類または含水低級ケトン類から再結晶することを特徴とするレボフロキサシン・1/2水和物の製法である。 That is, the present invention provides levofloxacin 1/2 hydrate characterized by recrystallizing levofloxacin from water-containing lower alcohols or water-containing lower ketones having a water content of 0.14% by volume or more and less than 4% by volume. It is a manufacturing method.
また本発明は、レボフロキサシンを、1容量%以上5容量%以下の濃アンモニア水を含むアンモニア水含有低級アルコール類またはアンモニア水含有低級ケトン類から再結晶することを特徴とするレボフロキサシン・1/2水和物の製法である。 The present invention also provides levofloxacin / 1/2 water characterized by recrystallizing levofloxacin from ammonia water-containing lower alcohols or ammonia water-containing lower ketones containing 1 to 5% by volume of concentrated aqueous ammonia. It is a manufacturing method of Japanese products.
本発明によれば、レボフロキサシン粗原料を、高収率でレボフロキサシン・1/2水和物に変えることが可能である。従って、種々の方法で製造したレボフロキサシン粗原料から、レボフロキサシン・1/2水和物を製造する方法として使用できるものである。 According to the present invention, it is possible to convert a levofloxacin crude raw material to levofloxacin 1/2 hydrate in a high yield. Therefore, it can be used as a method for producing levofloxacin 1/2 hydrate from levofloxacin crude raw materials produced by various methods.
本発明の一つの態様は、レボフロキサシン粗原料を、含水率が0.14容量%以上4容量%未満である含水低級アルコール類または含水低級ケトン類から再結晶するレボフロキサシン・1/2水和物の製法である。 In one embodiment of the present invention, levofloxacin 1/2 hydrate is obtained by recrystallizing a crude levofloxacin raw material from water-containing lower alcohols or water-containing lower ketones having a water content of 0.14% by volume or more and less than 4% by volume. It is a manufacturing method.
使用するレボフロキサシン粗原料としては、レボフロキサシンの1水和物や無水物が挙げられるが、これに限らず、不純物が含まれていたり、前記1水和物や無水物が混入した1/2水和物を粗原料としても良い。 The levofloxacin raw material to be used includes levofloxacin monohydrate and anhydride, but is not limited to this, and ½ hydrate containing impurities or mixed with the monohydrate or anhydride. Goods may be used as crude raw materials.
また、再結晶に使用できる溶媒(以下、「再結晶溶媒」という)は、少量の水と混和する溶媒で、レボフロキサシン粗原料が溶解するものであれば特に制限はなく、例えば無水メタノール、無水エタノール、イソプロパノール、ブタノール類の低級アルコール類や、アセトン、メチルエチルケトン等の低級ケトンを例示することが出来る。 The solvent that can be used for recrystallization (hereinafter referred to as “recrystallization solvent”) is not particularly limited as long as it is a solvent that is miscible with a small amount of water and can dissolve the levofloxacin raw material. For example, anhydrous methanol, anhydrous ethanol Examples thereof include lower alcohols such as isopropanol and butanol, and lower ketones such as acetone and methyl ethyl ketone.
この再結晶溶媒は、含水率が0.14容量%以上4容量%未満であることが必要であり、特に含水率が0.5容量%以上2容量%以下であることが好ましい。 The recrystallization solvent needs to have a water content of 0.14% by volume or more and less than 4% by volume, and particularly preferably has a water content of 0.5% by volume or more and 2% by volume or less.
再結晶溶媒として低級アルコール類を使用する場合は、レボフロキサシン粗原料に対しその4−8重量倍の範囲とすれば良く、通常は6−7重量倍が望ましい。また、再結晶溶媒として低級ケトンを使用する場合は、レボフロキサシン粗原料に対しその10−50重量倍の範囲とすれば良く、通常は20−30重量倍が望ましい。更に、再結晶溶媒の使用量は処理の開始当初から上記の量を使用する必要はなく、あらかじめ上記より多い量の再結晶溶媒に溶解した後に濃縮によって上記の量にしても良い。 When lower alcohols are used as the recrystallization solvent, the amount may be in the range of 4 to 8 times by weight with respect to the levofloxacin raw material, and usually 6 to 7 times by weight is desirable. When a lower ketone is used as the recrystallization solvent, it may be in the range of 10-50 times by weight of the raw levofloxacin raw material, and usually 20-30 times by weight is desirable. Furthermore, it is not necessary to use the above-mentioned amount from the beginning of the treatment, and the amount used for the recrystallization solvent may be adjusted to the above amount by dissolving in a larger amount of the recrystallization solvent in advance.
この再結晶溶媒にレボフロキサシン粗原料を溶解させるための加熱温度は、50℃から80℃の範囲であり、再結晶溶媒が低級アルコールである場合は、通常、75〜80℃程度の温度が好ましく、再結晶溶媒が低級ケトンである場合は、通常、50℃〜60℃が好ましい。また、溶解後の冷却温度は、25℃から−5℃の範囲であり、通常は5℃程度が好ましい。冷却時間は2時間から2昼夜の範囲でよく、好ましくは一昼夜である。 The heating temperature for dissolving the levofloxacin crude raw material in this recrystallization solvent is in the range of 50 ° C to 80 ° C, and when the recrystallization solvent is a lower alcohol, a temperature of about 75 to 80 ° C is usually preferable. When the recrystallization solvent is a lower ketone, it is usually preferably 50 ° C to 60 ° C. Moreover, the cooling temperature after melt | dissolution is the range of 25 degreeC to -5 degreeC, and about 5 degreeC is preferable normally. The cooling time may range from 2 hours to 2 days and nights, preferably day and night.
なお、レボフロキサシン・1/2水和物の再結晶は、レボフロキサシン粗原料が再結晶溶媒に加熱溶解した後、直ちに冷却し、静置して晶析させることが好ましい。 The recrystallization of levofloxacin 1/2 hydrate is preferably performed after the levofloxacin crude raw material is dissolved in a recrystallization solvent by heating, and then immediately cooled and allowed to stand for crystallization.
一方、本発明の別の態様は、レボフロキサシン粗原料を、1容量%以上5容量%以下、好ましくは、1.5容量%以上2.5容量%以下で濃アンモニア水(27%アンモニア水)を含むアンモニア水含有低級アルコール類またはアンモニア水含有低級ケトン類から再結晶するレボフロキサシン・1/2水和物の製法である。 On the other hand, in another embodiment of the present invention, concentrated levofloxacin raw material is concentrated 1% to 5% by volume, preferably 1.5% to 2.5% by volume of concentrated aqueous ammonia (27% aqueous ammonia). This is a process for producing levofloxacin 1/2 hydrate, which is recrystallized from ammonia water-containing lower alcohols or ammonia water-containing lower ketones.
この態様による発明は、再結晶溶媒として、上記のアンモニア水含有低級アルコール類またはアンモニア水含有低級ケトン類を使用する以外は、第一の態様の発明と同様にして実施することができる。すなわち、使用溶媒量、加熱温度および冷却温度も、前記した条件とほぼ同一でよい。 The invention according to this aspect can be carried out in the same manner as the invention according to the first aspect, except that the above ammonia water-containing lower alcohols or ammonia water-containing lower ketones are used as the recrystallization solvent. That is, the amount of solvent used, the heating temperature, and the cooling temperature may be substantially the same as described above.
なお、上記のように濃アンモニア水を含有させたアンモニア水含有低級アルコール類またはアンモニア水含有低級ケトン類(以下、「アンモニア含有再結晶溶媒」という)の含水量は、上記量の濃アンモニア水を加えることにより、概ね最初の態様の発明の条件をも満たすことができる。 The water content of the ammonia water-containing lower alcohols or ammonia water-containing lower ketones (hereinafter referred to as “ammonia-containing recrystallization solvent”) containing concentrated ammonia water as described above is the same as the amount of concentrated ammonia water. In addition, the conditions of the invention of the first aspect can be generally satisfied.
以上説明した本発明のレボフロキサシン・1/2水和物の製法は、その再結晶、晶析に先立って、精製工程を加えることもできる。例えば、レボフロキサシン粗原料の溶解後に、活性炭などを使用して脱色等の精製処理の工程を加えることも出来る。 The method for producing levofloxacin 1/2 hydrate according to the present invention described above can include a purification step prior to the recrystallization and crystallization. For example, after the levofloxacin crude raw material is dissolved, a purification process such as decolorization can be added using activated carbon or the like.
更に、本発明法で得られたレボフロキサシン・1/2水和物は、乾燥され、最終製品とされる。この結晶の乾燥は、目的物から溶媒のみを除去できる条件で行うことが好ましく、例えば、乾燥温度は20−45℃程度、好ましくは35−40℃程度であり、減圧度は5−100mmHg程度、好ましくは5−10mmHg程度である。また、乾燥時間はおよそ8時間程度が好ましく、乾燥法としては、逆円錐型スクリュー攪拌式真空乾燥機、縦型振動式真空乾燥機、あるいは棚段式箱形真空乾燥機などの各種の真空乾燥機を使用する乾燥法を挙げることができる。 Further, levofloxacin hemihydrate obtained by the method of the present invention is dried to obtain a final product. It is preferable to perform the drying of the crystals under conditions that can remove only the solvent from the target product. For example, the drying temperature is about 20-45 ° C., preferably about 35-40 ° C., and the degree of vacuum is about 5-100 mmHg. Preferably it is about 5-10 mmHg. The drying time is preferably about 8 hours, and various drying methods such as an inverted conical screw agitation vacuum dryer, a vertical vibration vacuum dryer, or a box-type box vacuum dryer can be used as the drying method. Mention may be made of a drying method using a machine.
かくして得られたレボフロキサシン・1/2水和物は、これを公知の医薬品担体と組み合わせることにより、種々の形態の抗菌剤とすることができる。 The thus obtained levofloxacin 1/2 hydrate can be made into various forms of antibacterial agents by combining it with a known pharmaceutical carrier.
次に実施例を挙げ、本発明を更に詳細に説明するが、本発明はこれにより何ら制約されるものではない。 EXAMPLES Next, although an Example is given and this invention is demonstrated still in detail, this invention is not restrict | limited at all by this.
実 施 例 1
100mLナス型フラスコに、レボフロキサシン粗原料(無水物;水分量0.994%)10gを秤取し、これに無水エタノール(含水量0.14v/v%)に2v/v%の水を加えて65mLとした溶液を加え、水浴で加熱した。レボフロキサシン粗原料は、77.3℃で溶解したので、その後放冷した。1昼夜室温で放冷後、減圧下濾取し、風乾した。レボフロキサシン・1/2水和物9.51gを得た。
Example 1
In a 100 mL eggplant-shaped flask, 10 g of levofloxacin crude raw material (anhydrous; water content: 0.994%) was weighed, and 2 v / v% water was added to absolute ethanol (water content: 0.14 v / v%). The solution made up to 65 mL was added and heated in a water bath. The crude levofloxacin raw material was dissolved at 77.3 ° C. and then allowed to cool. The mixture was allowed to cool at room temperature for one day and night, then filtered under reduced pressure and air-dried. 9.51 g of levofloxacin 1/2 hydrate was obtained.
水分値(カールフィッシャー法 平沼産業(株)製 AQ−55C):
2.56%(理論値 2.43%)
赤外線吸収スペクトル(日本分光(株)製 IR−5000):
1724, 1005カイザー
粉末X線結晶回折(2θ):
6.5°、9.5°、12.9°、13.5°、19.2°
Moisture value (Karl Fisher method Hiranuma Sangyo Co., Ltd. AQ-55C):
2.56% (theoretical value 2.43%)
Infrared absorption spectrum (IR-5000 manufactured by JASCO Corporation):
1724, 1005 Kaiser
Powder X-ray crystal diffraction (2θ):
6.5 °, 9.5 °, 12.9 °, 13.5 °, 19.2 °
実 施 例 2
100mLナス型フラスコに、レボフロキサシン粗原料(1/2水和物;水分量2.462%)10.00gを秤取し、これに無水エタノール(含水量0.14v/v%)70mLを加え、水浴で加熱した。レボフロキサシンは79℃で溶解したので、その後放冷した。1昼夜室温で放冷後、減圧下で濾取し、風乾した。レボフロキサシン・1/2水和物
9.41gを得た。
Example 2
To a 100 mL eggplant-shaped flask, weighed 10.00 g of crude levofloxacin raw material (1/2 hydrate; moisture content 2.462%), added 70 mL of absolute ethanol (water content 0.14 v / v%), Heated in a water bath. Levofloxacin was dissolved at 79 ° C. and then allowed to cool. The mixture was allowed to cool at room temperature for 1 day and then filtered under reduced pressure and air-dried. 9.41 g of levofloxacin 1/2 hydrate was obtained.
水分値(カールフィッシャー法 平沼産業(株)製 AQ−55C):
2.69%(理論値 2.43%)
赤外線吸収スペクトル(日本分光(株)製 IR−5000):
1724, 1006カイザー
粉末X線結晶回折(2θ):
6.5°、9.5°、12.9°、13.5°、19.2°
Moisture value (Karl Fisher method Hiranuma Sangyo Co., Ltd. AQ-55C):
2.69% (theoretical value 2.43%)
Infrared absorption spectrum (IR-5000 manufactured by JASCO Corporation):
1724, 1006 Kaiser X-ray powder diffraction (2θ):
6.5 °, 9.5 °, 12.9 °, 13.5 °, 19.2 °
実 施 例 3
100mLナス型フラスコに、レボフロキサシン粗原料(無水物;水分量0.9941%)10.00gを秤取し、これに無水エタノール(含水量0.14v/v%)に2v/v%の濃アンモニア水を加えて60mLとした溶液を加え、水浴で加熱した。レボフロキサシン粗原料は77.5℃で溶解したので、その後放冷した。1昼夜室温で放冷後、減圧下で濾取し、風乾した。レボフロキサシン・1/2水和物9.24gを得た。
Example 3
In a 100 mL eggplant-shaped flask, weighed 10.00 g of levofloxacin crude raw material (anhydrous; water content 0.9994%), and added 2v / v% concentrated ammonia to absolute ethanol (water content 0.14 v / v%). A solution was made up to 60 mL by adding water and heated in a water bath. Since the crude levofloxacin was dissolved at 77.5 ° C., it was then allowed to cool. The mixture was allowed to cool at room temperature for 1 day and then filtered under reduced pressure and air-dried. 9.24 g of levofloxacin 1/2 hydrate was obtained.
水分値(カールフィッシャー法 平沼産業(株)製 AQ−55C):
2.36%(理論値 2.43%)
赤外線吸収スペクトル(日本分光(株)製 IR−5000):
1724, 1006カイザー
粉末X線結晶回折(2θ):
6.5°、9.5°、12.9°、13.5°、19.2°
Moisture value (Karl Fisher method Hiranuma Sangyo Co., Ltd. AQ-55C):
2.36% (theoretical value 2.43%)
Infrared absorption spectrum (IR-5000 manufactured by JASCO Corporation):
1724, 1006 Kaiser X-ray powder diffraction (2θ):
6.5 °, 9.5 °, 12.9 °, 13.5 °, 19.2 °
実 施 例 4
500mLナス型フラスコにレボフロキサシン粗原料(無水物;水分量0.9941%)10.00gを秤取し、これに、アセトン(含水量0.07%)に水2%を含有させた溶媒260mLを加え、水浴で加熱した。レボフロキサシン粗原料は51.6℃で溶解したので、その後放冷した。1昼夜室温で放冷後、減圧下で濾取し、風乾した。レボフロキサシン・1/2水和物を6.80g得た。
Example 4
A levofloxacin crude raw material (anhydrous; water content of 0.9994%) (1.000 g) was weighed into a 500 mL eggplant-shaped flask, and 260 mL of a solvent containing acetone (water content 0.07%) and water 2% was added thereto. In addition, it was heated in a water bath. Since the crude levofloxacin was dissolved at 51.6 ° C., it was then allowed to cool. The mixture was allowed to cool at room temperature for 1 day and then filtered under reduced pressure and air-dried. 6.80 g of levofloxacin 1/2 hydrate was obtained.
水分値(カールフィッシャー法 平沼産業(株)製 AQ−55C):
2.688%(理論値 2.43%)
赤外線吸収スペクトル(日本分光(株)製 IR−5000):
1724, 1006カイザー
粉末X線結晶回折(2θ):
6.5°、9.5°、12.8°、13.5°、19.1°
Moisture value (Karl Fisher method Hiranuma Sangyo Co., Ltd. AQ-55C):
2.688% (theoretical value 2.43%)
Infrared absorption spectrum (IR-5000 manufactured by JASCO Corporation):
1724, 1006 Kaiser X-ray powder diffraction (2θ):
6.5 °, 9.5 °, 12.8 °, 13.5 °, 19.1 °
本発明方法により、レボフロキサシン粗原料からレボフロキサシン・1/2水和物を効率よく得ることができるので、レボフロキサシン・1/2水和物を有効成分とする抗菌剤を経済的に製造する方法として有利に使用することができるものである。
以 上
According to the method of the present invention, levofloxacin / 1/2 hydrate can be efficiently obtained from a raw levofloxacin raw material, which is advantageous as a method for economically producing an antibacterial agent containing levofloxacin / 1/2 hydrate as an active ingredient. It can be used for.
more than
Claims (12)
Levofloxacin was dissolved at a temperature of 75 to 80 ° C. in ethanol containing ammonia water containing 6 to 7 times its weight and concentrated ammonia water at 1.5 to 2.5% by volume. A process for producing levofloxacin 1/2 hydrate, characterized by cooling to room temperature.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005090485A JP2006273718A (en) | 2005-03-28 | 2005-03-28 | Method for producing levofloxacin-1/2 hydrate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005090485A JP2006273718A (en) | 2005-03-28 | 2005-03-28 | Method for producing levofloxacin-1/2 hydrate |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006273718A true JP2006273718A (en) | 2006-10-12 |
Family
ID=37208812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005090485A Pending JP2006273718A (en) | 2005-03-28 | 2005-03-28 | Method for producing levofloxacin-1/2 hydrate |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2006273718A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010016851A1 (en) * | 2008-08-02 | 2010-02-11 | Apeloa-Kangyu | Process for selectively producing a pyridobenzoxazine carboxylic acid hemihydrate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04234890A (en) * | 1990-03-01 | 1992-08-24 | Dai Ichi Seiyaku Co Ltd | Selective production of hydrate |
WO2003028664A2 (en) * | 2001-10-03 | 2003-04-10 | Teva Pharmaceutical Industries Ltd. | Preparation of levofloxacin and forms thereof |
WO2003045329A2 (en) * | 2001-11-29 | 2003-06-05 | Teva Pharmaceutical Industries Ltd. | Methods for the purification of levofloxacin |
JP2006111561A (en) * | 2004-10-14 | 2006-04-27 | Ohara Yakuhin Kogyo Kk | Method for producing 1/2 hydrate of antimicrobial agent |
-
2005
- 2005-03-28 JP JP2005090485A patent/JP2006273718A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04234890A (en) * | 1990-03-01 | 1992-08-24 | Dai Ichi Seiyaku Co Ltd | Selective production of hydrate |
WO2003028664A2 (en) * | 2001-10-03 | 2003-04-10 | Teva Pharmaceutical Industries Ltd. | Preparation of levofloxacin and forms thereof |
WO2003045329A2 (en) * | 2001-11-29 | 2003-06-05 | Teva Pharmaceutical Industries Ltd. | Methods for the purification of levofloxacin |
JP2006111561A (en) * | 2004-10-14 | 2006-04-27 | Ohara Yakuhin Kogyo Kk | Method for producing 1/2 hydrate of antimicrobial agent |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010016851A1 (en) * | 2008-08-02 | 2010-02-11 | Apeloa-Kangyu | Process for selectively producing a pyridobenzoxazine carboxylic acid hemihydrate |
US7964723B2 (en) | 2008-08-02 | 2011-06-21 | Apeloa-Kangyu | And practical process for exclusively producing (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido-[1,2,3,de][1,4]benzoxazine-6-carboxylic acid hemihydrate |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1873158B1 (en) | Crystals of morphinan derivative and process for producing the same | |
EA019304B1 (en) | Process for preparation of crystalline fipronil | |
JPH02191255A (en) | Preparation of stable modification of | |
JP5654462B2 (en) | Process for producing crystalline polymorph of 2- (3-cyano-4-isobutyloxyphenyl) -4-methyl-5-thiazolecarboxylic acid by a poor solvent addition method | |
CA2965716C (en) | Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof | |
BR112016011700B1 (en) | PROCESS FOR POMALIDOMIDE SYNTHESES | |
JP2006176515A (en) | Crystalline form of rabeprazole sodium | |
EP3257860A1 (en) | Crystal form of abiraterone propionate and preparation method therefor | |
NZ523528A (en) | Novel form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro-2-naphthyl}-4-morpholinobenzamide | |
CN102584693A (en) | Preparation method for high purity 2-chlorine-3-aminopyridine hydrochloride | |
JP2006273718A (en) | Method for producing levofloxacin-1/2 hydrate | |
CN107001284B (en) | A kind of crystal form and preparation method thereof of androgen receptor inhibitor | |
JP7068411B2 (en) | Hexadecyltreprostinyl crystal and its manufacturing method | |
KR102346516B1 (en) | Process for Preparing Crystal of Eldecalcitol | |
RU2529036C1 (en) | Method of producing palladium trifluoroacetate | |
CN106187799B (en) | A method of preparing DL-lysine hydrochloride | |
SK283188B6 (en) | Preparation method for crystalline form of 3/2 hydrate 7-[(7- (S)-amino-5-azaspiro[2.4]heptane-5-yl]-8-chloro-6-fluoro-1- [(1R,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3- carboxylic acid | |
RU2756568C1 (en) | Method for obtaining sodium salt of 5-amino-2,3-dihydro-1,4-phthalazinedione in hydrated or anhydrous form | |
KR20150042275A (en) | Pharmaceutical formulations containing 3-(4-cinnamyl-l-piperazinyl) amino derivatives of 3-formylrifamycin sv and 3-formylrifamycin s and a process of their preparation | |
JP3796481B2 (en) | Crystal polymorph of nafamostat mesylate and process for producing the same | |
JP5419570B2 (en) | Method for purifying 2-acetylaminomethyl-4- (4-fluorobenzyl) morpholine | |
JP2006111561A (en) | Method for producing 1/2 hydrate of antimicrobial agent | |
CN109535184B (en) | Method for preparing potassium clavulanate from clavulanic acid tert-octylamine | |
ZA200302520B (en) | Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl] piperazine.hydrochloride. | |
JP2010529094A (en) | Direct dissolution of docetaxel in solvent in polysorbate 80 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080208 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080208 |
|
A131 | Notification of reasons for refusal |
Effective date: 20110719 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
A02 | Decision of refusal |
Effective date: 20111220 Free format text: JAPANESE INTERMEDIATE CODE: A02 |